Revenue
2022
2023
2024
2025
Corvus Pharmaceuticals, Inc. (CRVS)
Price$12.23Cached quote
Net income
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2025
Total cash / debt
CashTotal debt
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — |
| Research & development | $33.7M | $19.4M | $16.5M | $24.5M | $29.1M | $31.8M | $38.0M | $38.6M | $46.3M | $29.4M | $11.4M | $38,000 |
| Operating expenses | $43.0M | $27.5M | $23.4M | $32.6M | $38.6M | $43.8M | $48.9M | $49.2M | $56.5M | $37.0M | $13.8M | — |
| Operating income | −$43.0M | −$27.5M | −$23.4M | −$32.6M | −$38.6M | −$43.8M | −$48.9M | −$49.2M | −$56.5M | −$37.0M | −$13.8M | −$161,000 |
| EBITDA | −$42.9M | −$27.5M | −$23.3M | −$32.2M | −$38.2M | −$43.1M | −$48.1M | −$48.4M | −$55.7M | −$36.4M | −$13.6M | — |
| Net income | −$15.3M | −$62.3M | −$27.0M | −$41.3M | −$43.2M | −$6.0M | −$46.7M | −$46.9M | −$55.7M | −$36.4M | −$31.3M | −$161,000 |
| Basic EPSper basic share | -$0.19 | -$1.02 | -$0.56 | -$0.89 | -$1.03 | -$0.20 | -$1.59 | -$1.71 | -$2.72 | -$2.36 | -$83.86 | -$0.95 |
| Diluted EPSper diluted share | -$0.53 | -$1.02 | -$0.56 | -$0.89 | -$1.03 | -$0.20 | -$1.59 | -$1.71 | -$2.72 | -$2.36 | -$83.86 | -$0.95 |
Owners
Reported shareholders
≈10.48%of listed shares
Thompson Peter A.8.82M shares · Jan 28, 2026
View holders
| Holder | % owned |
|---|---|
Thompson Peter A. | ≈10.48%8.82M shares |
ORBIMED ADVISORS LLC | 8.52%7.17M shares |
BlackRock, Inc. | 8.49%7.14M shares |
STATE STREET CORP | 5.32%4.47M shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 4.50%3.79M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.91%3.29M shares |
ADAMS STREET PARTNERS LLC | 3.89%3.28M shares |
Vivo Capital, LLC | 3.34%2.81M shares |
WELLINGTON MANAGEMENT GROUP LLP | 3.25%2.73M shares |
PERCEPTIVE ADVISORS LLC | 3.17%2.67M shares |
Deep Track Capital, LP | 2.96%2.49M shares |
MILLER RICHARD A MD | ≈2.77%2.33M shares |
BRAIDWELL LP | 2.53%2.13M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.20%1.85M shares |
Foresite Capital Management VI LLC | 2.18%1.83M shares |
GOLDMAN SACHS GROUP INC | 1.87%1.58M shares |
Hood River Capital Management LLC | 1.87%1.57M shares |
MORGAN STANLEY | 1.60%1.34M shares |
Boxer Capital Management, LLC | 1.31%1.1M shares |
Catalio Capital Management, LP | 1.28%1.08M shares |
Percentages use 84.12M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 11, 2026Form 4 | Moore David ScottDirector | BuyCommon Stock | 21.7K | $11.53 | $250.2K | 21.7K |
| May 18, 2026Form 4 | MILLER RICHARD A MDPresident and CEO | BuyCommon Stock · indirect | 1.9K | $12.01 | $23.2K | 1.20M |
| May 18, 2026Form 4 | MILLER RICHARD A MDPresident and CEO | BuyCommon Stock · indirect | 5.0K | $12.05 | $60.3K | 1.19M |
| Jun 27, 2025Form 4 | ORBIMED ADVISORS LLC +1Director,TenPercentOwner | SellCommon Stock · indirect | 1.18M | $4.16 | $4.89M | 7.17M |
| Jun 27, 2025Form 4 | Thompson Peter A.Director,TenPercentOwner | SellCommon Stock · indirect | 1.18M | $4.16 | $4.89M | 7.17M |